ARDT vs REGN · P/E 8.5, rev $6.32B vs P/E 14, rev $4.29B
Ardent Health Partners, Inc. (ARDT) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Ardent Health Partners, Inc. (ARDT) is a medical care facilities company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported ARDT revenue for 2025-12-31 was $6.32B. Net income was $135.8M. Revenue was up 6.0% from 2024-12-31 to 2025-12-31. ARDT currently screens at market cap $2.10B and trailing P/E 8.5.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
ARDT currently screens at market cap $2.10B and trailing P/E 8.5. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the ARDT and REGN stock pages for the full models.
Not investment advice.